Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
27.21
-0.43 (-1.56%)
Jul 31, 2026, 4:00 PM EDT - Market closed
LKFT Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 488.78 | 320.88 | 74.08 | 211.7 | -217.99 | -103.23 |
Depreciation & Amortization | - | 55.88 | - | 43.64 | 65.57 | 34.64 |
Stock-Based Compensation | - | 24 | - | 56.72 | 88.51 | 70.73 |
Other Adjustments | -110.36 | 280.18 | -170.79 | -66.68 | 63.88 | -25.17 |
Change in Receivables | - | 86.59 | - | -39.11 | 68.98 | 79.86 |
Changes in Inventories | - | 28.85 | - | -24.08 | -34.59 | -21.17 |
Changes in Accounts Payable | - | 33.81 | - | 31.82 | -2.08 | -35.35 |
Changes in Unearned Revenue | -1,012 | -1,071 | -255.51 | -661.06 | -383.62 | -453.72 |
Changes in Other Operating Activities | 103.48 | 199.7 | 35.79 | 26.56 | 20.26 | 13.03 |
Operating Cash Flow | -301.6 | -257.46 | -320.03 | -405.97 | -500.54 | -503.83 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -8.73 | -13.7 | -16.72 | -18.71 | -27.39 | -54.21 |
Sale of Property, Plant & Equipment | - | 0.46 | 0 | 2.43 | 0.74 | - |
Purchases of Intangible Assets | - | -0.16 | -65.39 | -0.57 | -9.56 | -3.67 |
Purchases of Investments | -3,176 | -3,465 | -3,386 | -3,404 | -2,729 | -1,561 |
Proceeds from Sale of Investments | 3,455 | 3,745 | 3,698 | 3,499 | 1,645 | 2,131 |
Cash Acquisitions | - | - | - | -7 | -115.27 | - |
Proceeds from Business Divestments | -10.15 | 19.43 | -8.95 | - | - | 28.7 |
Other Investing Activities | -18.5 | 0.95 | -3.6 | - | -38.16 | - |
Investing Cash Flow | 265.57 | 288.81 | 220.6 | 71.19 | -1,246 | 541.24 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Issuance of Common Stock | - | - | - | 1.77 | 6.7 | 3.31 |
Net Common Stock Issued (Repurchased) | - | - | - | 1.77 | 6.7 | 3.31 |
Other Financing Activities | -2.77 | -3.27 | -4.92 | -6.77 | -8.18 | -7.19 |
Financing Cash Flow | -2.77 | -3.27 | -4.92 | -5 | -1.49 | -3.88 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -2.46 | -4.46 | 1.78 | -1.52 | 22.29 | 56.76 |
Net Cash Flow | -38.81 | 28.09 | -104.35 | -339.79 | -1,748 | 33.54 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -310.33 | -271.16 | -336.75 | -424.68 | -527.93 | -558.03 |
Free Cash Flow Growth | - | - | - | - | - | - |
FCF Margin | -28.43% | -23.26% | -106.42% | -147.97% | -190.33% | -198.97% |
Free Cash Flow Per Share | -4.71 | -4.11 | -5.11 | -6.45 | -8.04 | -8.52 |
Levered Free Cash Flow | -428.42 | -445.9 | -162.36 | -390.13 | -579.85 | -620.02 |
Unlevered Free Cash Flow | -541.01 | -490.01 | -534.85 | -840.93 | -491.85 | -686.36 |